Title : Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.

Pub. Date : 2004 May

PMID : 15093573






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 HER2-positive patients received standard-dose trastuzumab plus epirubicin (60 or 90 mg/m(2))/cyclophosphamide (600 mg/m(2)) 3-weekly (EC60+H, n=26; EC90+H, n=25), for four to six cycles; 23 HER2-negative patients received EC alone (90/600 mg/m(2)) 3-weekly for six cycles (EC90). Epirubicin erb-b2 receptor tyrosine kinase 2 Homo sapiens